SARCLISA 20mg/mL concentrate for solution for infusion. clinical trials
4 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic confirmatory (Phase III)
MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
This study is looking at new ways to treat multiple myeloma, a type of blood cancer, in people under 66. It's testing if different treatment plans can better reduce the cancer to very low levels before further treatment. The aim is to find out which approaches work best for patients.
For: Multiple MyelomaBelgium · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma
This study is testing a new combination of medicines for people with multiple myeloma that has come back or hasn't responded to previous treatments. It aims to see how well these medicines work together to reduce the amount of cancer in the body.
For: Multiple MyelomaFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
This study compares a special stem cell treatment to standard care for people with multiple myeloma that has come back or worsened after their first treatment. It aims to see which approach helps people live longer and feel better over five years.
For: multiple myelomaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy
This study is testing a new combination of medicines for people with AL amyloidosis. It looks at how well the new treatment works and if it helps improve the disease, especially for those who haven't responded well to previous treatments.
For: AL AmyloidosisFrance